Fmr LLC Lowers Position in Grifols, S.A. (NASDAQ:GRFS)

Fmr LLC trimmed its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 22.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,646 shares of the biotechnology company’s stock after selling 7,074 shares during the quarter. Fmr LLC’s holdings in Grifols were worth $219,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in GRFS. GAMMA Investing LLC grew its position in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,135 shares during the period. NBC Securities Inc. boosted its stake in shares of Grifols by 2.8% during the 3rd quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 1,433 shares in the last quarter. Signaturefd LLC grew its position in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,153 shares during the period. US Bancorp DE increased its stake in shares of Grifols by 12.3% in the 3rd quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 2,256 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Grifols by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 31,543 shares of the biotechnology company’s stock valued at $280,000 after purchasing an additional 2,301 shares in the last quarter.

Analyst Ratings Changes

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Price Performance

Grifols stock opened at $7.51 on Friday. The stock has a market capitalization of $5.16 billion, a P/E ratio of 7.74 and a beta of 0.43. The company’s fifty day moving average price is $8.35 and its 200 day moving average price is $8.10. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.